Remimazolam in Current Anesthesia Practice

Cardiovascular Safety Profile

The American Society of Anesthesiologists notes that remimazolam demonstrates clear cardiovascular advantages compared to other sedative agents, with a lower incidence of hypotension, better hemodynamic stability, and a specific antagonist (flumazenil) available 1

The American Thoracic Society guidelines suggest that remimazolam has a significantly lower risk of respiratory depression compared to traditional midazolam, with a lower incidence of hypoxemia and better oxygen saturation 2, 3

The European Society of Anaesthesiology recommends that remimazolam's ultrarapid pharmacokinetics and predictability make it suitable for procedures requiring rapid recovery, with a specific antagonist (flumazenil) available for reversal 3

The American College of Cardiology recommends that remimazolam be considered for patients with cardiovascular instability or those at risk of respiratory depression, due to its favorable cardiovascular profile and reversibility with flumazenil 1
The American Society of Regional Anesthesia and Pain Medicine suggests that remimazolam may be beneficial in patients with difficult airways, due to its reversibility with flumazenil 3
The British Journal of Anaesthesia notes that remimazolam has a dosing regimen based on clinical experience, with a typical initial bolus dose of 30-110 µg/kg and a continuous infusion rate of 5-20 µg/kg/min, with careful titration recommended 4, 5

The European Heart Journal recommends midazolam over propofol during initial induction in patients with severe hemodynamic instability, due to its more favorable hemodynamic profile 6, 7
Midazolam has significant limitations, including a half-life of 3-11 hours, active metabolites that accumulate in renal dysfunction, and a high risk of delirium, which can be overcome by remimazolam 8, 9

Flumazenil can specifically reverse the effects of remimazolam, allowing for immediate termination of sedation if hemodynamic or respiratory deterioration occurs, which is particularly valuable in patients with difficult airways or critical cardiovascular instability 10, 11

In elderly patients, sedative drugs like remimazolam can cause confusion and oversedation, and these patients should be closely monitored, with dose reduction considered in patients over 60 years or with ASA III or higher 10, 11

The European Heart Journal guidelines establish fentanyl as the first-line treatment for ventilatory synchrony and shivering suppression in the post-cardiac arrest sedation algorithm, with propofol or midazolam used as needed, and remimazolam representing a potential evolution of this strategy 6, 7